KinoPharma

Focus: KinoPharma is a small-molecule focused pharmaceutical company founded in 2005 and headquartered in Tokyo, operating in the biotech space with an early-stage pipeline.

Biotech

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About KinoPharma

AI assessmentNot Hiring

No open roles listed right now. Follow KinoPharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

KNP2002

Common Wart

Phase 2

Clinical Trials (1)

NCT05896215OM202JP Clinical Study of KNP2002

Phase 2

Help build intelligence for KinoPharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to contribute to early-stage drug development in a focused small-molecule program (KNP2002 in Phase 2 for Common Wart)
Japanese pharma base provides potential exposure to Asia-Pacific market dynamics and regulatory pathways
Ground-floor involvement in a company with 19-year operational history but lean pipeline suggests potential for meaningful impact on core programs

Watch Out For

Extremely limited pipeline depth (only 1 active program) creates significant career risk if Phase 2 KNP2002 fails or stalls
Minimal hiring activity (1 open role in Auditing) and no disclosed revenue, funding, or financial stability suggest constrained growth and headcount expansion
Complete absence of published research, disclosed financials, and public information makes due diligence difficult and signals potential capital/visibility constraints

Generated by Claude from KinoPharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2005

Portfolio: 1 clinical trial

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo